Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Attenuation of Cardiac Effects of Arteriovenous Fistula Creation With Losartan

This study has been completed.
Information provided by:
Melbourne Health Identifier:
First received: March 8, 2007
Last updated: May 8, 2015
Last verified: May 2015

The primary objective is to determine if the use of losartan, an angiotensin II receptor blocker, can attenuate left ventricular hypertrophy, independent of its antihypertensive effects, in patients with near end stage chronic kidney disease (CKD) who have an arteriovenous fistula created.

Secondary outcomes include the impact of the medication on BNP and hyperkalaemia

Condition Intervention
Renal Failure
Left Ventricular Hypertrophy
Drug: losartan

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: Early and Late Cardiac Effects of Arteriovenous Fistula Creation for Haemodialysis in End-stage Renal Failure and Their Possible Attenuation

Resource links provided by NLM:

Further study details as provided by Melbourne Health:

Primary Outcome Measures:
  • left ventricular hypertrophy [ Time Frame: 3 months ]

Estimated Enrollment: 52
Study Start Date: October 2006
Study Completion Date: December 2014
Primary Completion Date: August 2014 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: losartan
    losartan 50 mg a day
Detailed Description:

Study Design: This is a prospective double blind placebo control 2 arm, randomized (1:1) parallel group study in patients with near end stage renal failure who require creation of an arteriovenous fistula for future haemodialysis. Enrolment will be over a period of 12 months. The blinded phase will be for 3 months. The study design is summarized in Appendix 1. The study consists of a screening phase, a randomization phase and a treatment phase.

Patients will be randomized into 2 groups:

  • Group 1 Losartan (50mg daily blinded) and 25 mg of atenolol
  • Group 2 Placebo (blinded) and 25 mg of atenolol

Patients: Patients must comply with specified inclusion and exclusion criteria. The number of patients used will be sufficient to show a 15% difference in the left ventricular mass (LVM) between the two groups

Study Endpoints: The primary endpoint is the between group difference in LVM from baseline to 1 month.

Statistical Considerations: The analysis will be based upon an 'ANCOVA'-type linear regression model that includes baseline LVM and treatment group as explanatory variables, and final LVM as the outcome variable.


Ages Eligible for Study:   18 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Diagnosis of CKD at near-end stage renal failure (CKD Stage IV) ( eGFR = 15-30 mls/min).
  2. Age >18 years of age and <85 years of age.
  3. Males and post-menopausal, sterile women. Non-pregnant pre-menopausal women should be on adequate contraception and have no intention of becoming pregnant during the duration of the study.
  4. At baseline TTE LVEF>45%
  5. Willing and able to give informed consent.

Exclusion Criteria:

  1. Serum potassium level of more than 5.5 mmol/L
  2. Acute myocardial infarction or cerebrovascular accident in the previous 6 months.
  3. Severe uncontrolled hypertension (diastolic BP >100mmHg or systolic BP >160 mmHg)
  4. Evidence or suspicion of renovascular disease.
  5. Atrial fibrillation
  6. Evidence or suspicion of collagen disease, cancer, psychiatric disorder that interferes with patient compliance, drug or alcohol abuse, pregnancy, breast feeding and ineffective contraception.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00602004

Royal Melbourne Hospital
Parkville, Australia, 3150
Sponsors and Collaborators
Melbourne Health
Principal Investigator: Anuradha Aggarwal Melbourne Health
Principal Investigator: Eugenia Pedagogos, FRACP,PhD Melbourne Health
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Dr Anuradha Aggarwal, Royal Melbourne Hospital Identifier: NCT00602004     History of Changes
Other Study ID Numbers: 2006.059
Study First Received: March 8, 2007
Last Updated: May 8, 2015

Keywords provided by Melbourne Health:
Arteriovenous fistula

Additional relevant MeSH terms:
Renal Insufficiency
Arteriovenous Fistula
Hypertrophy, Left Ventricular
Pathological Conditions, Anatomical
Kidney Diseases
Urologic Diseases
Arteriovenous Malformations
Vascular Malformations
Cardiovascular Abnormalities
Cardiovascular Diseases
Vascular Fistula
Vascular Diseases
Congenital Abnormalities
Heart Diseases
Anti-Arrhythmia Agents
Antihypertensive Agents
Angiotensin II Type 1 Receptor Blockers
Angiotensin Receptor Antagonists
Molecular Mechanisms of Pharmacological Action processed this record on April 28, 2017